DK2069395T3 - Nye antigener og antistoffer associeret med adenokarcinom i pancreaskanalen - Google Patents

Nye antigener og antistoffer associeret med adenokarcinom i pancreaskanalen

Info

Publication number
DK2069395T3
DK2069395T3 DK07820692.7T DK07820692T DK2069395T3 DK 2069395 T3 DK2069395 T3 DK 2069395T3 DK 07820692 T DK07820692 T DK 07820692T DK 2069395 T3 DK2069395 T3 DK 2069395T3
Authority
DK
Denmark
Prior art keywords
antibodies
pda
adenocarcinoma
pancreatic duct
identified
Prior art date
Application number
DK07820692.7T
Other languages
Danish (da)
English (en)
Inventor
Francesco Novelli
Barbara Tomaino
Paola Cappello
Original Assignee
Ribovax Biotechnologies Sa
Bioline Diagnostici Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribovax Biotechnologies Sa, Bioline Diagnostici Srl filed Critical Ribovax Biotechnologies Sa
Application granted granted Critical
Publication of DK2069395T3 publication Critical patent/DK2069395T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G01N33/57525—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK07820692.7T 2006-09-29 2007-09-28 Nye antigener og antistoffer associeret med adenokarcinom i pancreaskanalen DK2069395T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06121552 2006-09-29
EP06126726 2006-12-20
PCT/EP2007/060305 WO2008037792A1 (en) 2006-09-29 2007-09-28 Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma

Publications (1)

Publication Number Publication Date
DK2069395T3 true DK2069395T3 (da) 2012-05-14

Family

ID=38895810

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07820692.7T DK2069395T3 (da) 2006-09-29 2007-09-28 Nye antigener og antistoffer associeret med adenokarcinom i pancreaskanalen

Country Status (18)

Country Link
US (1) US8071721B2 (enExample)
EP (1) EP2069395B1 (enExample)
JP (1) JP2010505104A (enExample)
KR (1) KR20090094227A (enExample)
CN (1) CN101578295B (enExample)
AT (1) ATE542831T1 (enExample)
AU (1) AU2007301966B2 (enExample)
BR (1) BRPI0717282A2 (enExample)
CA (1) CA2664841A1 (enExample)
DK (1) DK2069395T3 (enExample)
EA (1) EA016731B1 (enExample)
ES (1) ES2381304T3 (enExample)
IL (2) IL197868A (enExample)
NO (1) NO20091662L (enExample)
NZ (1) NZ576409A (enExample)
PL (1) PL2069395T3 (enExample)
PT (1) PT2069395E (enExample)
WO (1) WO2008037792A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500964A (ja) * 2008-05-09 2012-01-12 デューク ユニバーシティ 癌の検出と治療における自己抗体
IT1398782B1 (it) 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
ITTO20120523A1 (it) * 2012-06-15 2013-12-16 Natimab Therapeutics S R L Procedimento e kit per la diagnosi in vitro dell'adenocarcinoma duttale pancreatico o per determinare la predisposizione all'adenocarcinoma duttale pancreatico
RU2656153C1 (ru) * 2013-12-20 2018-05-31 Девелопмент Сентер Фор Байотекнолоджи Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии
MX2016009102A (es) 2014-01-13 2016-09-09 Berg Llc Composiciones de enolasa 1 (eno1) y sus usos.
CN115786317A (zh) * 2022-12-12 2023-03-14 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753446A (en) * 1993-04-15 1998-05-19 National Jewish Center For Immunology & Respiratory Medicine Mitogen ERK kinase kinase (MEKK) assay

Also Published As

Publication number Publication date
WO2008037792A1 (en) 2008-04-03
PL2069395T3 (pl) 2012-06-29
IL197868A0 (en) 2011-08-01
IL197868A (en) 2013-03-24
CA2664841A1 (en) 2008-04-03
AU2007301966B2 (en) 2013-02-21
EA200970332A1 (ru) 2009-10-30
EP2069395A1 (en) 2009-06-17
EP2069395B1 (en) 2012-01-25
PT2069395E (pt) 2012-04-27
NO20091662L (no) 2009-06-29
ES2381304T3 (es) 2012-05-25
IL218442A0 (en) 2012-04-30
KR20090094227A (ko) 2009-09-04
ATE542831T1 (de) 2012-02-15
JP2010505104A (ja) 2010-02-18
CN101578295B (zh) 2013-02-27
BRPI0717282A2 (pt) 2013-10-15
US20100028907A1 (en) 2010-02-04
EA016731B1 (ru) 2012-07-30
US8071721B2 (en) 2011-12-06
CN101578295A (zh) 2009-11-11
AU2007301966A1 (en) 2008-04-03
NZ576409A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
MY162056A (en) Diagnosis and treatment of cancer using anti -ereg antibody
CY1117236T1 (el) Μονοκλωνικα αντισωματα εναντι γλυπικανης-3
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
PH12015500093A1 (en) Il-17 binding proteins
IL218442A0 (en) Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
EP1996716A4 (en) MANIPULATED ANTI-PROSTATE STEAM CELL RESPONSIVES (PSCA) ANTIBODIES FOR CANCER TARGETING
CY1118714T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2
CY1119539T1 (el) Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1
MX2024003355A (es) Anticuerpos anti-cd3.
MX2008009886A (es) Anticuerpos que enlazan par-2.
EA201492253A1 (ru) Конструкторы, связывающиеся с ron, и способы их использования
BRPI0808940A8 (pt) anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
EA201070179A1 (ru) Антиген, связанный с вариантами рака легкого и лимфомами
EA201001212A1 (ru) Лечение микробных инфекций
NO20084795L (no) Fremgangsmate for a behandle, diagnostisere eller detektere kreft
EA200702361A1 (ru) АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ
ATE542915T1 (de) Cst-ii-modifzierungen für erhöhte proteinexpression
BR112012022641A2 (pt) peptídeos hjurp e vacinas que incluem os mesmos
MX342000B (es) Peptidos ect2 y vacunas que los incluyen.
MY192517A (en) Antibody specifically binding to pauf protein and use thereof
DE602007013234D1 (de) Verfahren und zusammensetzungen zur diagnose und behandlung von krebs